PCM
TBPH icon

Peregrine Capital Management’s Theravance Biopharma TBPH Stock Holding History

Peregrine Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-459,716
Closed -$6.67M – 345
2021
Q2 		$6.67M Sell
459,716
-24,490
-5% -$460K 0.12% 253
2021
Q1 		$9.88M Sell
484,206
-67,624
-12% -$1.29M 0.18% 233
2020
Q4 		$9.81M Buy
551,830
+139,236
+34% +$2.5M 0.19% 233
2020
Q3 		$6.1M Sell
412,594
-39,361
-9% -$737K 0.16% 203
2020
Q2 		$9.49M Buy
+451,955
New +$11.6M 0.27% 134

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Peregrine Capital Management's TBPH Position: Q3 2021 in Review

Peregrine Capital Management sold out of Theravance Biopharma (TBPH) in Q3 2021, closing a stake of 459,716 shares — an estimated $6.67M sold.

Peregrine Capital Management first reported a position in TBPH in Q2 2020 and held it in 5 quarters. The position peaked at $9.88M in Q1 2021. 119 funds tracked by Wall St. Rank hold TBPH as of Q3 2021.

  • Peregrine Capital Management reported no remaining Theravance Biopharma position as of Q3 2021 after selling out during the quarter.
  • Peregrine Capital Management sold 459,716 Theravance Biopharma shares in Q3 2021, an estimated $6.67M.
  • Peregrine Capital Management first reported a position in Theravance Biopharma in Q2 2020 and held it in 5 quarters.
  • Peregrine Capital Management's Theravance Biopharma position peaked at $9.88M in Q1 2021.
  • 119 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2021.

Based on Peregrine Capital Management's 13F filing for Q3 2021, filed 2 Nov 2021.